Page 2506 - Williams Hematology ( PDFDrive )

2477
2476 Index Index 2477

Phosphodiesterases, 1885 PIAS (protein inhibitor of activated STATs), smoldering myeloma, 1708–1709, 1725,
Phosphofructokinase (PFK) 253 1734f, 1761
activity, 692t Pica, 120, 632 solitary plasmacytoma, 1497t, 1733, 1760
deficiency, 690, 700t, 704 Pickwickian syndrome, 876, 882 Waldenström macroglobulinemia. See
in glucose metabolism, 694–695 PIGA, 571, 572–573, 574–575, 577, 1346t Waldenström macroglobulinemia
Phosphoglucomutase, 692t, 701t Pim-1, 218 (WM)
6-Phosphogluconate dehydrogenase, 692t, PIM1, 1626 Plasma cells
697, 701t PIN1 (peptidylprolyl isomerase), 951 antigens, 1141, 1141f
6-Phosphogluconolactonase, 692t, 697, 701t Piperacillin-tazobactam, 384, 387t composition, 1145
3-Phosphoglycerate, in glucose metabolism, Pipobroman, for essential thrombocythemia, development, 61, 1710f
692–693, 695 1313t, 1314 generation of, 1171–1172
Phosphoglycerate kinase (PGK) Piroxicam, 2075 in immunoglobulin synthesis regulation,
activity, 692t Pituitary gland 1171–1172
deficiency, 700t, 704–705 anemia and, 560–561 marrow, 32t, 35
in glucose metabolism, 695 in Langerhans cell histiocytosis, 1104, structure, 1137, 1138f, 1140
Phosphoglycerate mutase, 695 1105, 1106 Plasma coagulation factors, in neonate,
Phosphoglycolate phosphatase, 692t Pituitary gland, primary lymphomas in, 1579 109–111
Phosphoinositide/phosphoinositol/ PK. See Pyruvate kinase (PK) Plasmacytoid dendritic cells, 309
phosphatidylinositol 3-kinase PK (prekallikrein), 1929, 2121 Plasmacytoid lymphocytes, 1203f
(PI3K) PKC (protein kinase C), 1016, 1178, 1837, Plasmacytoma, 1497t, 1760
in eosinophils, 951 1841 Plasma derivatives, 2366, 2368
in Hodgkin lymphoma, 1606 PKC-β, 235t Plasma exchange
inhibitors, 1403 PKC-θ deficiency, 2058 adverse effects, 431, 2257
in mantle cell lymphoma, 1654 PLA (phospholipase A ), 1016, 1876 for atypical hemolytic uremic syndrome,
2
2
in platelets, 1833t, 1882 Placental growth factor, 801 2261
Phosphoinositide/phosphoinositol/ Plaque for autoimmune hemolytic anemia, 839
phosphatidylinositol 3-kinase atherosclerotic. See Atherosclerosis for cryoglobulinemia, 428
(PI3K) inhibitors, 1529, 1538 cutaneous, 1680, 1681f definition, 427
Phospholipase A, 1970 Plasma for HELLP syndrome, 802–803
Phospholipase A (PLA ), 1016, 1876 in aplastic anemia, 519 for hyperviscosity, 428
2
2
Phospholipase β, 1874 in myelodysplastic syndromes, 1353 indications for, 427–428, 428t, 429–430t
Phospholipase C (PLC), 1016, 1874, 2057– platelet storage in, 2388–2389, 2388t for myeloma cast nephropathy, 428
2058 in polycythemia vera, 1295 for neuropathy, 1724
Phospholipase Cβ (PLC-β ) deficiency, in primary myelofibrosis, 1327 principles, 427, 430f, 431f
2
2
2057–2058 Plasmablastic lymphoma, 1246, 1496t for thrombotic microangiopathies, 428,
Phospholipase Cγ (PLC-γ ), 1178, 1529 Plasma cell leukemia, 1736t, 1737, 1743f, 431
1
1
Phospholipase Cγ (PLCγ ), 1538 1746 for thrombotic thrombocytopenic
2
2
Phospholipase δ, 1874 Plasma cell myeloma, 188, 1497t purpura, 2256
Phospholipase γ, 1874 Plasma cell neoplasms Plasma factor concentrations, in older
Phospholipids classification, 1497t persons, 135
activated protein C and, 1956 cytogenetic assessment techniques, Plasma labels, 489
arterial thrombosis and, 2294 1711–1712 Plasmalyte, 2389, 2389t
in erythrocyte membrane, 662 definition and history, 1707 Plasmapheresis, 427, 544, 2368. See also
in erythrocytes, 469t essential monoclonal gammopathy. See Plasma exchange
in neutrophils, 1016 Essential monoclonal gammopathy Plasma proteins, in pregnancy, 119–120
in platelets, 1836, 1854 etiology and pathogenesis, 1708–1710 Plasma thromboplastin component (PTC),
Phosphomannose isomerase, 692t immunoglobulin light-chain amyloidosis. 2113. See also Factor IX
Photochemotherapy/photopheresis, See Immunoglobulin light-chain Plasma tissue-type plasminogen, aging and,
extracorporeal, 429t, 433, 1687 (AL) amyloidosis 135
Photodynamic therapy, 1686 light chain deposition disease, 1744, Plasma volume, 488–489
Photosensitivity, 897, 898 1760 Plasmin
Phototherapy, 857, 1686 minimal residual disease assessment, disorders of generation of, 2311–2312
Physical examination, 7–9 1716–1717 in fibrinolysis and angiogenesis, 2311
PI3K. See Phosphoinositide/phosphoinositol/ myeloma. See Myeloma fibrinolytic actions of, 2304f, 2309–2311,
phosphatidylinositol 3-kinase POEMS syndrome (osteosclerotic 2310f
(PI3K) myeloma), 9, 1733, 1746 in inflammatory response, 290

Kaushansky_index_p2393-2506.indd 2477 9/21/15 3:22 PM